Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use YORVIPATH safely and effectively. See full prescribing information for YORVIPATH. YORVIPATH ® (palopegteriparatide) injection, for subcutaneous use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
YORVIPATH is indicated for the treatment of hypoparathyroidism in adults. Limitations of Use YORVIPATH was not studied for acute post-surgical hypoparathyroidism. YORVIPATH's titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment [see Dosage and Administration (2.3, 2.4) and Clinical Studies (14)].
- generic_name
- palopegteriparatide
- product_names
- Palopegteriparatide
- ndc
- 73362-100, 73362-100-03, 73362-100-02, 73362-100-01, 73362-101, 73362-101-03, 73362-101-02, 73362-101-01, 73362-102, 73362-102-03, 73362-102-02, 73362-102-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en